Oragenics develops improved intranasal formulation for concussion drug ONP-002

ORAGENICS INC

New formulation of ONP-002 designed to enhance brain uptake via nasal cavity, potentially reducing concussion symptoms.
Oragenics reports increased final dose levels and improved intranasal adhesion for longer absorption times.
Phase II study in concussed patients being planned to assess safety, feasibility, and effectiveness using blood biomarkers.
Concussion is a serious unmet need with 69 million cases annually worldwide; leads to long-term disability in up to 20%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.